LXRX
Price
$0.62
Change
-$0.01 (-1.59%)
Updated
Jun 2 closing price
Capitalization
225.75M
58 days until earnings call
MNKD
Price
$4.29
Change
+$0.14 (+3.37%)
Updated
Jun 2 closing price
Capitalization
1.3B
64 days until earnings call
Interact to see
Advertisement

LXRX vs MNKD

Header iconLXRX vs MNKD Comparison
Open Charts LXRX vs MNKDBanner chart's image
Lexicon Pharmaceuticals
Price$0.62
Change-$0.01 (-1.59%)
Volume$2.29M
Capitalization225.75M
MannKind
Price$4.29
Change+$0.14 (+3.37%)
Volume$2.01M
Capitalization1.3B
LXRX vs MNKD Comparison Chart
Loading...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LXRX vs. MNKD commentary
Jun 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LXRX is a Buy and MNKD is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 03, 2025
Stock price -- (LXRX: $0.62 vs. MNKD: $4.29)
Brand notoriety: LXRX and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LXRX: 28% vs. MNKD: 103%
Market capitalization -- LXRX: $225.75M vs. MNKD: $1.3B
LXRX [@Biotechnology] is valued at $225.75M. MNKD’s [@Biotechnology] market capitalization is $1.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $307.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LXRX’s FA Score shows that 0 FA rating(s) are green whileMNKD’s FA Score has 0 green FA rating(s).

  • LXRX’s FA Score: 0 green, 5 red.
  • MNKD’s FA Score: 0 green, 5 red.
According to our system of comparison, MNKD is a better buy in the long-term than LXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LXRX’s TA Score shows that 4 TA indicator(s) are bullish while MNKD’s TA Score has 4 bullish TA indicator(s).

  • LXRX’s TA Score: 4 bullish, 4 bearish.
  • MNKD’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, LXRX is a better buy in the short-term than MNKD.

Price Growth

LXRX (@Biotechnology) experienced а -5.80% price change this week, while MNKD (@Biotechnology) price change was +4.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.09%. For the same industry, the average monthly price growth was +1.10%, and the average quarterly price growth was -0.30%.

Reported Earning Dates

LXRX is expected to report earnings on Jul 31, 2025.

MNKD is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+4.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNKD($1.3B) has a higher market cap than LXRX($226M). LXRX YTD gains are higher at: -15.829 vs. MNKD (-33.281). MNKD has higher annual earnings (EBITDA): 82.6M vs. LXRX (-184.29M). LXRX has more cash in the bank: 238M vs. MNKD (182M). MNKD has less debt than LXRX: MNKD (47.2M) vs LXRX (108M). MNKD has higher revenues than LXRX: MNKD (298M) vs LXRX (31.1M).
LXRXMNKDLXRX / MNKD
Capitalization226M1.3B17%
EBITDA-184.29M82.6M-223%
Gain YTD-15.829-33.28148%
P/E RatioN/A42.90-
Revenue31.1M298M10%
Total Cash238M182M131%
Total Debt108M47.2M229%
FUNDAMENTALS RATINGS
LXRX vs MNKD: Fundamental Ratings
LXRX
MNKD
OUTLOOK RATING
1..100
1054
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
54
Fair valued
PROFIT vs RISK RATING
1..100
10046
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8687
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNKD's Valuation (54) in the Biotechnology industry is in the same range as LXRX (55). This means that MNKD’s stock grew similarly to LXRX’s over the last 12 months.

MNKD's Profit vs Risk Rating (46) in the Biotechnology industry is somewhat better than the same rating for LXRX (100). This means that MNKD’s stock grew somewhat faster than LXRX’s over the last 12 months.

MNKD's SMR Rating (100) in the Biotechnology industry is in the same range as LXRX (100). This means that MNKD’s stock grew similarly to LXRX’s over the last 12 months.

LXRX's Price Growth Rating (86) in the Biotechnology industry is in the same range as MNKD (87). This means that LXRX’s stock grew similarly to MNKD’s over the last 12 months.

LXRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MNKD (100). This means that LXRX’s stock grew similarly to MNKD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LXRXMNKD
RSI
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 6 days ago
83%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 13 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
87%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ACCOX10.25N/A
N/A
American Century International Val C
SGSCX30.18N/A
N/A
DWS Global Small Cap S
DURCX13.73N/A
N/A
DWS ESG International Core Eq C
PWJDX33.50N/A
N/A
PGIM Jennison International Opps R4
REIGX16.15N/A
N/A
Federated Hermes International Growth R6